| P644 | Checkpoint inhibitor therapy in solid organ and allogeneic stem cell transplantation: data mining of The Truven Health Marketscan Research Database | Noha Abdel-Wahab, MD, PhD; Ala Abudayyeh; Xiudong Lei; Gheath Alatrash, DO, PhD; Hui Zhao; Sharon H. Giordano; Houssein Safa, MD; Daniel H. Johnson, MD; Van A. Trinh, DPharm; Maen Abdelrahim, MD, PhD; Ahmed O. Gaber, MD; Maria Suarez-Almazor, MD, PhD; Adi Diab, MD; | Checkpoint blockade; Epidemiology; Immune toxicity |
| P645 | Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury | Hamzah Abu-Sbeih, M.D.; Tenglong Tang, MD; Yinghong Wang, MD, PhD; | Checkpoint blockade; Clinical study; Immune suppression; Immune toxicity |
| P646 | Discovery and characterization of therapeutic human monoclonal antibodies against 17 immuno-oncology targets using microfluidics and molecular genomics | Adam Adler, PhD; Rena Mizrahi, PhD; Carter R. Keller, MBA; David Johnson, PhD | Antibody; B cell; Checkpoint blockade; Coinhibition; Costimulation |
| P647 | DuoBody-PD-L1x4-1BB combines checkpoint blockade and 4-1BB co-stimulation to promote antigen-specific T-cell stimulation and proliferation | Isil Altintas, PhD; Alexander Muik, PhD; Isil Altintas, PhD; Friederike Gieseke; Theodora Salcedo; Saskia Burm; Mustafa Diken, PhD; Christian Grunwitz; Sebastian Kreiter, MD; David Satijn, PhD; Danita Schuurhuis; Ozlem Tureci; Esther Breij, PhD; Ugur Sahin, MD | Antibody; Coinhibition; Costimulation; Cytokine; Tumor infiltrating lymphocytes (TILs) |
| P648 | Different exhausted t-cell subsets exhibit different degrees of dysfunction in follicular lymphoma | Theodora Anagnostou, MD; Zhi Zhang Yang, MD; Hyo Jin Kim, PhD; Jose C. Villasboas, MD; Tammy L. . Price-Troska; Shahrzad Jalali, PhD; Anne J. Novak, PhD; Stephen M. Ansell, MD, PhD; | Checkpoint blockade; T cell; Tumor microenvironment |
| P649 | Resistance to PD1 blockade in the absence of metalloprotease-mediated LAG3 shedding | Lawrence P. Andrews, PhD; Ashwin Somasundaram, MD; Jessica Moskovitz, MD; Andrea L. Szymczak; Chang Liu, PhD; Anthony R. Cillo, PhD; Brenda F. Kurland; Huang Lin; Kelly D. Moynihan, PhD; Darrell J. Irvine, PhD; Robert L. Ferris, MD, PhD; Tullia C. Bruno, PhD; Creg Workman, PhD; Dario A. Vignali, PhD | Checkpoint blockade; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P650 | Selective CD47 immune checkpoint targeting on tumor cells modulates the tumor microenvironment to enhance macrophage tumoricidal function | Vanessa Buatois, PhD; Xavier Chauchet, PhD; Laura Cons; Laurence Chatel; Limin Shang, PhD; Marie H. Kosco-Vilbois; Krzysztof Masternak, PhD; Nicolas Fischer, PhD; Walter G. Ferlin, PhD | Antibody; Checkpoint blockade; Leukemia/Lymphoma; Monocyte/Macrophage; Myeloid cells; Solid tumors; Tumor microenvironment |
| P651 | First-in-human study of FAZ053, an anti-PD-L1 mAb, alone and in combination with spartalizumab, an anti-PD-1 mAb, in patients with advanced malignancies | Filip Janku, MD, PhD; David SP. Tan; Juan Martin-Liberal; Shunji Takahashi; Ravit Geva, MD; Ayca Gucalp; Xueying Chen; Kulandayan Subramanian; Jennifer Mataraza; Jennifer Wheler; Philippe Bedard, MD | Antibody; Checkpoint blockade; Clinical trial; Solid tumors |
| P652 | Cytokine-mediated induction of PD-L1 expression on tumor and immune cells | Shuming Chen, PhD; George A. Crabill, MS; Theresa S. Pritchard, MS; Tracee L. McMiller, MS; Drew M. Pardoll, MD, PhD; Fan Pan; Suzanne L. Topalian, MD | Checkpoint blockade; Cytokine; Immune suppression; Monocyte/Macrophage; Tumor evasion; Tumor microenvironment |
| P653 | Discovery of a novel TIGIT therapeutic antibody with strong efficacy in tumor xenografts as monotherapy | Feifei Cui, PhD; Lei Fang; Zhengyi Wang; Taylor B. Guo; Jingwu Zang | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs) |
| P654 | T-cell profiling in cancer tissue with multiplexed IHC using UltiMapper™ I/O assays | Sean R. Downing, PhD; Alexis Wong, PhD; Amy Zhang, M.S.; Max Rubinstein; Laura Sciarra, PhD; Chakib Boussahmain, Mr., B.S; Bonnie Phillips, PhD; Katir K. Patel, PhD; Stephanie Hennek, PhD | Antibody; Biomarkers; Immune contexture; Immune monitoring; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment; Tumor stroma |
| P656 | ATOR-1017, a tumor directed Fcγ-receptor cross linking dependent 4-1BB agonistic antibody | Karin Enell Smith, PhD; Anna Rosén; Karin Barchan; Ida Aberg; Doreen Werchau, BS; Mia Thagesson; Anna Dahlman; Niina Veitonmaki; Christina Furebring, PhD; Peter Ellmark, PhD | Antibody; Costimulation; Leukemia/Lymphoma; NK/NK T cell; Solid tumors; T cell |
| P657 | Agonist redirected checkpoint platform (ARC), engineering bi-functional fusion proteins (PD1-Fc-OX40L), for cancer immunotherapy | George J. Fromm, Jr., PhD; Suresh de Silva, Ph.D.; Taylor H. Schreiber, MD, PhD; | Checkpoint blockade; Costimulation; Cytokine; Immune suppression; T cell; Tumor antigens |
| P658 | Agonist redirected checkpoint platform (ARC), engineering bi-functional fusion proteins (TIM3-Fc-OX40L and TIM3-Fc-CD40L), for cancer immunotherapy | George J. Fromm, Jr., PhD; Suresh de Silva, Ph.D.; Taylor H. Schreiber, MD, PhD; | Antigen presenting cells; Checkpoint blockade; Costimulation; Cytokine; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens |
| P659 | AGEN2373 is a conditionally-active agonist antibody targeting the co-stimulatory receptor CD137 for the treatment of human malignancies | Claire H. Galand, PhD; David Savitsky, PhD; Vignesh Venkatraman; Min Lim; Rebecca Ward, MSc; Nicholas S. Wilson; Christina Riordan; Matthew Costa; Randi B. Gombos, PhD; Benjamin Morin, PhD; Dhan Chand, PhD | Antibody; Costimulation; NK/NK T cell; T cell; Tumor microenvironment |
| P660 | A novel bispecific agent targeting PD-L1 and IL-15/IL-15Ralpha promotes potent anti-tumor efficacy in multiple models of human solid carcinomas | Karin M. Knudson, PhD; Kristin C. Hicks, PhD; Yohei Ozawa, MD, PhD; Jeffrey Schlom, PhD; John Lee, MD; Shahrooz Rabizadeh, PhD; Patrick Soon-Shiong, MD, FRCS, FACS; Sofia Gameiro, PharmD, PhD | Checkpoint blockade; Cytokine; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P661 | Quantitative cell-based reporter gene bioassays to advance individual or combination cancer immunotherapy | Jamison J. Grailer, PhD; Jun Wang; Julia Gilden, PhD; Pete Stecha; Denise Garvin; Michael Beck; Jim Hartnett; Frank Fan, PhD; Mei Cong, PhD; Zhi-jie J. Cheng, PhD | Antibody; Checkpoint blockade; Coinhibition; Costimulation; T cell |
| P662 | A phase 1a/b study investigating novel anti-PD-L1 antibody (LY3300054): interim safety and clinical activity in patients with advanced cancers. | Antoine Hollebecque, MD; Hyun Cheol Chung, MD, PhD; Marcus O. Butler, MD; Antoine Italiano, MD; Chia-Chi Lin, MD, PhD; Jean-Pascal Machiels, MD, PhD; Wu-Chou Su, MD; Marc Peeters, MD, PhD; Leijun Hu, PhD; Anna M. Szpurka, PhD; Danni Yu, PhD; Anindya Chatterjee, PhD; Burkhard Vangerow, MD; Shivani Nanda, MS; Yumin Zhao, PhD; Mythili Koneru, MD; Yung-Jue Bang, MD PhD; Antoine Hollebecque, MD; Antoine Hollebecque, MD | Antibody; Biomarkers; Clinical study; Solid tumors; Targeted therapy |
| P663 | Successful monitoring of checkpoint inhibitors by flow cytometry | Laila-Aicha Hanafi; Valerie Hebert; Delphine Labit; Jean-Francpos Poulin, PhD, MBA; Vicky Sgouroudis, PhD; Philippe Pouliot, PhD | Checkpoint blockade; Immune monitoring; Immune suppression; T cell |
| P664 | Simultaneous checkpoint - checkpoint or checkpoint - costimulatory receptor targeting with bispecific antibodies promotes enhanced human T cell activation | Michael Hedvat, PhD; Gregory L. Moore, PhD; Matthew J. Bernett, PhD; Christine Bonzon, PhD; Kendra N. Avery, PhD; Rumana Rashid, PhD; Alex Nisthal, PhD; Umesh Muchhal, PhD; John R. Desjarlais, PhD | Antibody; Checkpoint blockade; Coinhibition; Costimulation; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P665 | Anti-tumor synergy evaluation of an AZD4635/ anti-PD-L1 combination therapy using a quantitative systems model | Veronika Voronova, MSc; Lulu Chu, PhD; Yuri Kosinsky, PhD; Alexandra Borodovsky, PhD; Richard Woessner, PhD; Kris Sachsenmeier, PhD; Ganesh Mugundu, PhD; Melinda S. Merchant, MD, PhD; Wenlin Shao, PhD; Kirill Peskov, PhD; Gabriel Helmlinger, PhD; | Antigen presenting cells; Checkpoint blockade; T cell; Tumor microenvironment |
| P666 | Antitumor efficacy of anti-TIGIT antagonist antibody EOS884448 is mediated by a dual mechanism of action involving restoration of T cell effector functions and preferential depletion of Tregs. | Chaterine Hoofd; Julia Cuende, PhD; Virginie Rabolli, PhD; Julie Preillon, MSc; Noemie Wald, PhD; Lucile Garnero; Florence Lambolez, PhD; Marjorie Mercier; Shruthi Prasad, PhD; Florence Nyawame; Sofie Denies, PhD; Margreet Brouwer, MSc; Erica Houthuys, PhD; Veronique Bodo, PhD; Xavier Leroy, PhD; Scott Chappel; Michel Detheux, PhD; Gregory Driessens, PhD; Chaterine Hoofd; Olivier de Henau; | Antibody; Checkpoint blockade; NK/NK T cell; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P667 | EOS100850, an insurmountable and non-brain penetrant A2A receptor antagonist, inhibits adenosine-mediated T cell suppression, demonstrates anti-tumor activity and shows best-in class characteristics. | Erica Houthuys, PhD; Stefano Crosignani, PhD; Reece Marillier, PhD; Theo Deregnaucourt, MSc; Margreet Brouwer, MSc; Romain Pirson, MSc; Joao Marchante, MSc; Annelise Hermant, MSc; Florence Nyawouame, MSc; Julie Preillon, MSc; Kim Frederix, PhD; Anne-Catherine Michaux, MSc; Jakub Swiercz, PhD; Gregory Driessens, PhD; Noemie Wald, PhD; Chiara Martinoli, PhD; Veronique Bodo, PhD; Michel Detheux, PhD; Xavier Leroy, PhD | Checkpoint blockade; Immune suppression; T cell; Tumor evasion; Tumor microenvironment |
| P668 | Selection of optimized drug candidates, dosing regimen, pharmacodynamic endpoints, tumor types, and biomarkers for translating inhibition of the adenosine pathway into effective anti-tumor activity | Juan C. Jaen, PhD; Jay P. Powers, PhD; Ulrike Schindler, PhD; Steve W. Young, PhD; Matthew J. Walters, PhD; Joanne BL. Tan, PhD; Lisa Seitz, MSc | Checkpoint blockade; Clinical trial; Immune suppression; Immune tolerance; T cell; Tumor microenvironment |
| P669 | First-in-human Phase 1 study of INCMGA00012 in patients with advanced solid tumors: Interim results of the cohort expansion phase | Janice J. Mehnert, MD; Anthony Joshua, MD; Nehal Lakhani, MD, PhD; Udai Banerji; Drew Rasco; Iwona Lugowska; Monika Tomaszewska-Kiecana; Elena Garralda; Deanna Kornacki, PhD; Bradley J. Sumrow; Mark Cornfeld, MD, MPH; Chuan Tian; John D. Powderly, II, MD, CPI | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| P671 | Discovery of a novel anti-LAG3 antagonist antibody | Wenqing Jiang, PhD; Lei Fang; Zhengyi Wang; Taylor B. Guo; Jingwu Zang; | Checkpoint blockade; Coinhibition; T cell |
| P672 | Discovery and development of a humanized monoclonal antibody targeting the CD73 immune checkpoint for cancer immunotherapy | H. Toni Jun, Ph.D.; Fen Pei, Ph.D.; Hui Zou, Ph.D.; Ming Wang, Ph.D.; | Antibody; Checkpoint blockade; Coinhibition; Immune suppression; Immune tolerance; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion; Tumor microenvironment |
| P673 | Preliminary results from an ongoing phase 1 study of AB122, an anti-programmed cell death-1 (PD-1) monoclonal antibody, in patients with advanced solid tumors | Paul de Souza, MBBS, MPH, PHD, FRACP; Chee Khoon Lee; Katrin Sjoquist; Shu Pan; Amanda Idan; Aimee K. Rieger, B.S.; Wade Berry, BA; Lixia Jin; Lisa Seitz, MSc; Devika Ashok, PhD; Matthew J. Walters, PhD; Dana Piovesan, MSc; Joanne BL. Tan, PhD; Susan J. Lee, PhD; Adam Park, BS; Daniel DiRenzo, PhD; Joyson Karakunnel, MD, MSc | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Immune suppression; Solid tumors; Tumor evasion; Tumor microenvironment |
| P674 | Defining Tim-3 signaling and localization during T cell activation | Shunsuke Kataoka, Ph.D; Lawrence P. Kane, Ph.D. | Antigen presenting cells; Costimulation; T cell |
| P675 | Mechanisms of primary resistance to immune checkpoint blockade | Duane Moogk, PhD; Michelle Krogsgaard, PhD; Kaitao Li, PhD; Zhou Yuan, PhD; Shi Zhong, PhD; Zhiya Yu; Ivan Liadi; William Rittase, PhD; Victoria Fang, BS; Janna Dougherty, BS; Arianne Perez-Garcia, PhD; Iman Osman; Jeffrey S. Weber, MD, PhD; Navin Varadarajan, PhD; Nicholas P. Restifo, MD; Alan Frey, PhD; Cheng Zhu, PhD; | Biomarkers; Checkpoint blockade; Immune suppression; Proteomics; T cell; Targeted therapy |
| P676 | Targeting the sialoglycan/Siglec pathway in combination with checkpoint inhibitors for cancer immunotherapy | Michal Stanczak; Natalia Rodrigues Mantuano; Adam Petrone; Melissa Anne Gray; Carolyn Bertozzi; Li Peng, PhD; Alfred Zippelius, MD; Heinz Läubli, MD PhD | Checkpoint blockade; Coinhibition; T cell; Tumor infiltrating lymphocytes (TILs); Tumor evasion |
| P677 | The antitumor efficacy of TIM-3 blockade in a murine model of sarcoma | Kristen McEachern, PhD; Geeta Sharma; Srimoyee Ghosh, PhD; Sridhar Ramaswamy, MD; David Jenkins, PhD | Checkpoint blockade; Coinhibition |
| P678 | Targeting Siglec-15 with NC318, a novel therapeutic antibody to enhance anti-tumor immunity | Linda N. Liu, PhD; Jun Wang, PhD; Jingwei Sun, PhD; Dallas Flies, PhD; Chang Song, PhD; Melissa Zarr, PhD; Kristina Archer, PhD; Alison McGuire, BS; Tom O'Neill, MS; Karla Maloveste, MS; Xinxin Nie, PhD; Agedi Boto, MD/PhD; Ron Copeland, PhD; Sathya Janardhanan, MS; Tete Obot, BS; Jim Bingham, PhD; Kevin N. Heller, MD; Sol Langermann, PhD; Lieping Chen, MD, PhD; | Antibody; Checkpoint blockade; Coinhibition; Costimulation; Immune suppression; Monocyte/Macrophage; Solid tumors; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P679 | Neuropilin-1 is a T cell memory checkpoint limiting long-term tumor immunity | Chang Liu, PhD; Ashwin Somasundaram, MD; Tullia C. Bruno, PhD; Creg Workman, PhD; Dario A. Vagnali | Checkpoint blockade; Immune suppression; T cell; Tumor evasion |
| P681 | A translational platform using primary human immune cells in vitro, syngeneic and humanized models in vivo to support and advance immune-oncology drug discovery | Shilina Roman; Gary Salmon; Julie Hawkins; Jonathan White, PhD; Julia Lloyd; Ria Goodwin; Arunima A. Ganguli, PhD; Omar Aziz; Julia Schueler; Ian Waddell; Martin O'Rourke; Edgar R. Wood, Ph.D. | Antibody; Checkpoint blockade; Cytokine; Immune adjuvant; Immune monitoring; Inflammation; Monocyte/Macrophage; Stem cell/cancer-initiating cell; T cell; Tumor microenvironment |
| P682 | Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy | Saman Maleki Vareki; Steven F. Gameiro; Farhad Ghasemi; John W. Barrett; James Koropatnick; Anthony C. Nichols; Joe S. Mymryk | Bioinformatics; Biomarkers; Checkpoint blockade; Costimulation; Dendritic cell; Immune monitoring; Solid tumors; Surgery; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P683 | The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation | Anne Mansson Kvarnhammar, PhD; Niina Veitonmäki; Karin Hagerbrand, PhD; Mia Thagesson; Doreen Werchau, BS; Kristine Smedenfors; Anna Dahlman; Anna Rosen, MSc; Maria Johansson; Ida Åberg; Per Norlen, MD, PhD; Christina Furebring, PhD; Peter Ellmark, PhD | Antibody; Checkpoint blockade; Costimulation; Regulatory T cell (Treg cell); T cell |
| P684 | Preclinical studies of TIM-3 blockade supporting clinical development of BMS-986258, an anti‒TIM-3 monoclonal antibody | Xiao Min Schebye, PhD; Minhua Han; Hong-An Truong; Andy Deng; Alan J. Korman, PhD; Mark Selby, PhD; Christine Bee | Antibody; Checkpoint blockade; T cell; Tumor infiltrating lymphocytes (TILs) |
| P685 | CD226 impact on TIGIT blockade in T-cell rejuvenation | Katherine G. MacDonald, PhD; Yoon Park; Padma Perkins; Eric Boyer; Salvatore Santino; Michael Hamilton; Ishita Barman; Pavel Strop; Alan J. Korman, PhD; Bryan Barnhart, PhD | Antibody; Checkpoint blockade; Immune suppression; T cell; Tumor infiltrating lymphocytes (TILs) |
| P686 | The number of metastatic compartments involved at immunotherapy initiation may influence survival in stage-IV non-small cell lung cancer. | Abdul Rafeh Naqash, MD; Mahvish Muzaffar, MD; Paul R. Walker, MD; Li V. Yang, PhD | Antibody; Checkpoint blockade; Clinical study; Tumor microenvironment |
| P687 | Single-cell analysis of human T cells in the bladder tumor microenvironment reveals novel cytotoxic CD4s that are modulated by anti-PD-L1 therapy | David Y. Oh, MD, PhD; Serena Kwek; Siddharth S. Raju, BS; Tony Li, BS; Eric Chow, PhD; Arun Burra, BS; Chien-Chun S. Pai, PhD; Chiara Rancan, PhD; Yang Sun, PhD; Jacky Li, BS; Dvir Aran, PhD; Matthew Spitzer, PhD; Serghei Mangul, PhD; Sima Porten, MD; Maxwell V. Meng, MD; Terence Friedlander, MD; Chun Jimmie Ye, PhD; Lawrence Fong, MD | Bioinformatics; Biomarkers; Immune contexture; Immune monitoring; Solid tumors; Systems biology; T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P688 | Peripheral blood profiling to identify predictors of sensitivity to anti–PD-1 blockade in non-small cell lung cancer | Akio Osa; shohei koyama, MD PhD; Yujiro Naito; Takeshi Uenami; Masahide Mori; Atsushi Kumanogoh | Checkpoint blockade; Immune monitoring; T cell |
| P690 | Pharmacokinetics (PK) and dosing regimen selection of the PD-1 Inhibitor ABBV-181 in patients with advanced solid tumors: Preliminary Phase 1 results from study M15-891 | Apurvasena Parikh, PhD; Sreeneeranj Kasichayanula, PHD; Rajeev Menon; Daniel Afar, PhD; Stacie L. Lambert; Benjamin Engelhardt; Sven Mensing; | Antibody; Checkpoint blockade; Clinical study; Clinical trial; Solid tumors; T cell |
| P691 | Correlating skin toxicity and steroid treatment with outcomes of Anti-PD-1 therapy | Henry Quach, BS; Anna K. Dewan, MD; Douglas B. Johnson, MD, MSCI; | Autoimmunity; Checkpoint blockade; Coinhibition; Immune suppression; Immune toxicity; Inflammation; Solid tumors; Targeted therapy |
| P692 | Effect of steroids in metastatic non-small cell lung cancer (mNSCLC) patients treated with nivolumab after initial platinum therapy in community practices in the United States | Jenine K. Sanzari, PhD; Marc Monté; David A. Smith; Mark Danese; Michelle Gleeson; Deborah Lubeck; James White; Pranav Abraham; Beata Korytowsky; Brian Ulrich | Checkpoint blockade; Clinical study; Solid tumors |
| P693 | Efficacy of ex-vivo PD-1 blockade in cervical tumor draining lymph nodes is related to a CD8+FoxP3+ T-cell subset with high levels of multiple immune checkpoints and superior effector functions | Jossie Rotman, MD; Marijne Heeren, MSc; Anita Stam; Noëlle Pocorni, MsC; Awa Gassama; Sanne Samuels, MD, PhD; Maaike Bleeker; Stijn Mom, MD PhD; Henry Zijlmans, MD PhD; Gemma G. Kenter, MD,PhD; Ekaterina S. Jordanova, PhD; Tanja D. de Gruijl, PhD; | Biomarkers; Checkpoint blockade; Immune monitoring; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor antigens; Tumor microenvironment |
| P694 | An orally bioavailable small molecule dual antagonist of TIGIT and PD-L1 pathways shows immune-mediated anti-tumor activity | Pottayil Sasikumar, PhD; Sudarshan Naremaddepalli, PhD; Sandeep Patil, PhD; Chennakrishnareddy Gundala; Raghuveer K. Ramachandra, PhD; Nagesh Gowda, PhD; Saikrishna Tangela; Sreenivas Adurthi, PhD; Amit Dhudashia, MSc; Dodheri Samiulla, PhD; Nagaraj Gowda, PhD; Kavitha Nellore; Murali Ramachandra, PhD | Checkpoint blockade; Coinhibition |
| P695 | Differential expression of microRNAs in immune cell subpopulations during checkpoint inhibitor treatment | Barbara Seliger, MD, PhD; Rolf Kiessling, MD, PhD | Antigen presenting cells; Checkpoint blockade; Immune monitoring; T cell |
| P696 | Combined anti-PD-1 and anti-LAG-3 checkpoint blockade enhances CD8+ TIL effector function while reducing Tregs leading to reduced immune suppression and improved overall survival | Elizabeth R. Sturgill, PhD; Courtney Mick, BS; Elizabeth R. Sturgill, PhD; David Jenkins, PhD; Johanna K. Kaufmann, PhD, MSc; William L. Redmond, PhD; | Antibody; Checkpoint blockade; Immune suppression; Regulatory T cell (Treg cell); T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment |
| P697 | Preclinical characterization of AB154, a fully humanized anti-TIGIT antibody, for use in combination therapies | Joanne BL. Tan, PhD; Amy Anderson, PhD; Daniel DiRenzo, PhD; Annette Becker, PhD; Susan J. Lee, PhD; Lisa Seitz, MSc; Rick Stanton, MSEE; Hema Singh; Sharon Zhao; Nigel PC. Walker, PhD; Matthew J. Walters, PhD | Checkpoint blockade; Coinhibition; Gene expression; Immune monitoring; NK/NK T cell; Regulatory T cell (Treg cell); T cell |
| P698 | Outcomes of advanced triple negative breast cancer patients enrolled in immune oncology clinical trials | Tira Tan, MBBS; Lisa Wang; David Cescon; Eitan Amir; David Warr; Christine Elser; Marcus O. Butler, MD; Albiruni R. Razak; Aaron Hansen; Anna Spreafico, MD PhD; Lillian Siu, MD; Philippe Bedard, MD; | Checkpoint blockade; Chemotherapy; Clinical study; Solid tumors |
| P699 | MEDI0562, a humanized OX40 agonist monoclonal antibody (mAb), increases T cell effector function and depletes regulatory T cells in blood and tumor | Katie Streicher, PhD; Keith E. Steele, DVM, PhD; Steven Eck, Ph.D.; Yanan Zheng, PhD; Farzad Sekhavati, PhD; Han Si; Fernanda Pilataxi; Song Wu, PhD; Brandon W. Higgs, PhD; Danielle Townsley; Rakesh Kumar, PhD; Mike Sheehan, PhD; Scott Hammond, PhD; Matthew Gribbin; Victoria Chiou, MD; Maria Jure-Kunkel; Sandip P. Patel, MD; John D. Powderly, II, MD, CPI; Bonnie S. Glisson, MD; Koustubh Ranade, PhD | Clinical trial; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor microenvironment |
| P700 | Immune checkpoint inhibitors induce differential anti-tumor response and immune cell infiltration across syngeneic models | Patrick Allison, PhD; Hua-Chen Chang; Lauren B. Ursic, BA; Paul Trampont, PhD; Lindsey Standarski; Jennifer L. Rusk, NA; Brandy Wilkinson, PhD | Checkpoint blockade; Myeloid cells; Regulatory T cell (Treg cell); Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
| P701 | Off-label use of immunotherapy in advanced malignancies | David Xu; Kathryn Gold, MD; Lyudmila Bazhenova, MD; Sandip P. Patel, MD | Checkpoint blockade |
| P702 | Acute liver injury in the context of immune checkpoint inhibitor-related colitis treated with infliximab | Hao Chi Zhang, MD; Wenyi Luo, MD; Yinghong Wang, MD, PhD; | Checkpoint blockade; Immune toxicity; Inflammation |
| P703 | Exploration of PD-1/PD-L1 spatial interaction and T cells functionality to predict anti-PD-1 treatment outcome in GI tract tumors using automated quantitative fluorescence multiplexed IHC | Xiangxue Wang, B.S.; Shizen Moh, B.S.; José L. Muñoz-Rodríguez, PhD; Antony Hubbard, BS; Mehrnoush Khojasteh, PhD; Qingfeng Zhu, PhD; Robert A. Anders, MD, PhD; Luis A. Diaz, MD; Lidija Pestic-Dragovich; Lei Tang, PhD; Wenjun Zhang, MD, PhD; | Antibody; Biomarkers; Checkpoint blockade; Immune contexture; Immune suppression; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs); Tumor microenvironment; Tumor stroma |
| P704 | Batf3 dendritic cells within the tumor microenvironment are necessary during the effector phase of the immune response for anti-PD-L1 efficacy through a mechanism involving the 4-1BB/4-1BB ligand axis | Andrea Ziblat, PhD; Brendan L. Horton; Philip C. He, BA; Thomas F. Gajewski, MD, PhD; | Checkpoint blockade; Costimulation; Dendritic cell; T cell |
| O44 | FS120 mAb2, a dual agonist bispecific antibody targeting OX40 and CD137, activates T cells in vitro and induces potent, FcγR-independent anti-tumour activity | Miguel Gaspar, PhD; Cyril Privezentzev, PhD; Katy Everett, PhD; Sandra Uhlenbroich; John Pravin; Leonor LR. Rodrigues, MSc; Delphine Buffet; Marine Houee; Francisca Wollerton; Melanie Medcalf; Edouard Souteyrand; Alexander Koers, PhD; Emma McConnell, Master in Phyhsiology and Pharmacology for Researc; Martyn C. Rhoades, Mateusz Wydro, PhD; Maud Berthelot, MSc; Sarah Batey; Michael Davies; Jacqueline F. Doody, PhD; Michelle Morrow, PhD; Mihriban Tuna, PhD; Neil Brewis, PhD | Antibody; Costimulation; Immune adjuvant; Regulatory T cell (Treg cell); T cell; T cell lineages |
| O45 | Refractory renal cell cancer (RCC) exhibits high adenosine A2A receptor (A2AR) expression and prolonged survival following treatment with the A2AR antagonist, CPI-444 | Lawrence Fong, MD; John D. Powderly, II, MD, CPI; Jason J. Luke, MD, FACP; Drew Hotson, PhD; Mario Sznol, MD; Saby George, MD, FACP; Toni K. Choueiri; Brian I. Rini, MD; Matthew Hellmann, MD; Shivaani Kummar, MD; Leonel Hernandez-Aya, MD PhD; Daruka Mahadevan, MD, PhD; Brett Hughes, MD; Ben Markman; Matthew Riese, MD, PhD; Joshua Brody, MD; Daniel Renouf, MD; Rebecca Heist, MD; Rachel Goodwin, MD; Amy Weise, DO; Leisha A. Emens, MD, PhD; Stephen Willingham, PhD; Long Kwei, PhD; Ginna G. Laport, MD; Richard A. Miller, MD | Checkpoint blockade; Clinical study; Clinical trial; Solid tumors |
| O46 | Increased tumor-resident memory T cells in breast cancer is associated with improved prognosis | Peter Savas; Balaji Virassamy; Chengzhong Ye; Agus Salim; Chris Mintoff; Franco Caramia; Roberto Salgado; Zhi Ling Teo; Sathana Dushyanthen; Ann Byrne; Stephen J. Luen; Paul Beavis, PhD; Stephen B. Fox; Phillip K. Darcy; Terence P. Speed; Laura K. Mackay; Paul J. Neeson, PhD; Paul J. Neeson, PhD; Sherene Loi, MD, PhD | T cell; T cell lineages; Tumor infiltrating lymphocytes (TILs) |
| O47 | Peripheral T cell dynamics in resectable NSCLC patients treated with neoadjuvant PD-1 blockade | Jiajia Zhang, MD, MPH; Zhicheng Ji; Margueritta El Asmar, MD; Justina Caushi; Valsamo Anagnostou, MD PhD; Hok Yee N. Chan, MS; Prerna Suri, MS; Haidan N. Guo, BS, and BA; Kristen Marrone, MD; Jarushka Naidoo, MD; Taha Merghoub, PhD; Jamie Chaft, MD; Matthew Hellmann, MD; Janis M. Taube, MD, MSC; Julie R. Brahmer, MD; Victor E. Velculescu, MD, PhD; Ni Zhao; Patrick Forde, MD; Drew M. Pardoll, MD, PhD; Hongkai Ji; Kellie N. Smith, PhD | Bioinformatics; Checkpoint blockade; Clinical trial; Neoantigens; Solid tumors; T cell; Tumor infiltrating lymphocytes (TILs) |
